142 related articles for article (PubMed ID: 14751353)
1. Geographic distribution of prostate cancer incidence in the era of PSA testing, Connecticut, 1984 to 1998.
Gregorio DI; Kulldorff M; Sheehan TJ; Samociuk H
Urology; 2004 Jan; 63(1):78-82. PubMed ID: 14751353
[TBL] [Abstract][Full Text] [Related]
2. [Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)].
Cepeda Piorno J; Rivas del Fresno M; Fuente Martín E; González García E; Muruamendiaraz Fernández V; Fernández Rodríguez E
Arch Esp Urol; 2005 Jun; 58(5):403-11. PubMed ID: 16078781
[TBL] [Abstract][Full Text] [Related]
3. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer incidence in light of the spatial distribution of another screening-detectable cancer.
Gregorio DI; Samociuk H
Spat Spatiotemporal Epidemiol; 2013 Sep; 6():1-6. PubMed ID: 23973176
[TBL] [Abstract][Full Text] [Related]
5. Early-stage prostate cancer, PSA screening rates decline.
Printz C
Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
[No Abstract] [Full Text] [Related]
6. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
7. [Transrectal prostatic biopsy management policy for patients older than 50 years in relation to PSA values elaborated by a mathematical decision tree].
Santos Arrontes D; Cortés Aránguez I; Begara Morillas F; Fernández Arjona M; de Castro Barbosa F
Arch Esp Urol; 2005 Jun; 58(5):413-6. PubMed ID: 16078782
[TBL] [Abstract][Full Text] [Related]
8. The role of increasing detection in the rising incidence of prostate cancer.
Potosky AL; Miller BA; Albertsen PC; Kramer BS
JAMA; 1995 Feb; 273(7):548-52. PubMed ID: 7530782
[TBL] [Abstract][Full Text] [Related]
9. New circulating biomarkers for prostate cancer.
Bensalah K; Lotan Y; Karam JA; Shariat SF
Prostate Cancer Prostatic Dis; 2008; 11(2):112-20. PubMed ID: 17998918
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
11. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing.
Jacobsen SJ; Katusic SK; Bergstralh EJ; Oesterling JE; Ohrt D; Klee GG; Chute CG; Lieber MM
JAMA; 1995 Nov; 274(18):1445-9. PubMed ID: 7474190
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of prostate cancer in the Umbria region of Italy: evidence of opportunistic screening effects.
La Rosa F; Stracci F; Minelli L; Mastrandrea V
Urology; 2003 Dec; 62(6):1040-4. PubMed ID: 14665351
[TBL] [Abstract][Full Text] [Related]
13. Evidence of increased prostate cancer detection in men aged 50 to 59: a review of 324,684 biopsies performed between 1995 and 2002.
Lowe FC; Gilbert SM; Kahane H
Urology; 2003 Dec; 62(6):1045-9. PubMed ID: 14665352
[TBL] [Abstract][Full Text] [Related]
14. The significance of PSA/IGF-1 ratio in differentiating benign prostate hyperplasia from prostate cancer.
Koliakos G; Chatzivasiliou D; Dimopoulos T; Trachana V; Paschalidou K; Galiamoutsas V; Triantos A; Chitas G; Dimopoulos A; Vlatsas G
Dis Markers; 2000; 16(3-4):143-6. PubMed ID: 11381196
[TBL] [Abstract][Full Text] [Related]
15. [Prostate Specific Antigen (PSA), yet how much damage?].
Braillon A; Hill C; Dubois G
Presse Med; 2012 May; 41(5):482-5. PubMed ID: 22336482
[TBL] [Abstract][Full Text] [Related]
16. [PSA-screening: sensible or meaningless?].
Dubben HH
Urologe A; 2009 Sep; 48(9):1103; author reply 1103-4. PubMed ID: 19727645
[No Abstract] [Full Text] [Related]
17. Screening for adenocarcinoma of the prostate.
Elias PH
Mayo Clin Proc; 2006 Jan; 81(1):132; author reply 132-3. PubMed ID: 16438491
[No Abstract] [Full Text] [Related]
18. [Statistical study of probabilities of rectal palpation, total PSA, and PSA density in prostate cancer].
Ortiz Cabria R; Adriazola Semino M; Tejeda Bañez E; Alonso Villalba A; García Cobo E; Romero Rodríguez F; Monfá Bosch JM
Arch Esp Urol; 2002; 55(1):35-40. PubMed ID: 11957749
[TBL] [Abstract][Full Text] [Related]
19. [Prostate cancer screening using prostate-specific antigen (PSA) determinations in plasma. National Academy of Medicine].
Bourel M; Ardaillou R;
Bull Acad Natl Med; 2003; 187(5):985-95. PubMed ID: 14979060
[TBL] [Abstract][Full Text] [Related]
20. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
Telesca D; Etzioni R; Gulati R
Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
